Unassociated Document
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 12b-25
 

NOTIFICATION OF LATE FILING

(Check One):
o Form 10-K and Form 10-KSB
o Form 20-F
o Form 11-K
 
x Form 10-Q and Form 10-QSB
o Form N-SAR
  
 
For Period Ended: May 31, 2008

o Transition Report on Form 10-K
o Transition Report on Form 10-Q
o Transition Report on Form 20-F
o Transition Report on Form N-SAR
o Transition Report on Form 11-K
  
 
For the Transition Period Ended :________________________
 
Read attached instruction sheet before preparing form. Please print or type.
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. 
 
If the notification related to a portion of the filing checked above, identify the item(s) to which the notification relates:
 
 
PART I
REGISTRANT INFORMATION
 
Full name of registrant:    Oramed Pharmaceuticals Inc.                                        
 
Former name if applicable: Integrated Security Technologies, Inc.
 
Address of principal executive office (street and number): Hi-Tech Park 2/5 Givat Ram, PO Box 39098
 
City, state and zip code:   Jerusalem, Israel 91390
 
 
 
 

PART II
RULE 12b-25 (b) and (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

x
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense.
     
x
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K, Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
     
 
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
 
PART III
NARRATIVE
 
State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.
 
Oramed Pharmaceuticals Inc. (the “Registrant”) is unable to file its Quarterly Report on Form 10QSB for the quarter ended May 31, 2008 (the “Form 10QSB”) by the initial filing deadline of July 15, 2008 without unreasonable effort and expense because the Registrant has encountered a delay in assembling the information, in particular its financial statements for the quarter ended May 31, 2008, required to be included in its May 31, 2008 Form 10QSB. The Registrant intends to have the Form 10QSB filed as soon as practicable, and in no event later than the fifth calendar day following the prescribed due date.

 
PART IV
OTHER INFORMATION
 
 
(1)
Name and telephone number of person to contact in regard to this notification: Nadav Kidron, Chief Executive Officer at 972-2-566-0001.

 
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s)
x Yes o No            
 
 
2
 
 
 
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
 o Yes x No            
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reason why a reasonable estimate of the results cannot be made.
 
Oramed Pharmaceuticals Inc. 
(Name of Registrant as specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
     
Date: July 16, 2007  By:   /s/ Nadav Kidron 
 
Nadav Kidron
  Chief Executive Officer 
 
 
 
3